Cemiplimab

• Drug Class: Monoclonal antibody; PD-1 immune checkpoint inhibitor
• Indications:
  • Approved for advanced cutaneous squamous cell carcinoma (CSCC)
  • Also used in non-small cell lung cancer (NSCLC) and basal cell carcinoma, among other cancers2
• Mechanism of Action:
  • Blocks PD-1 receptor on T cells, enhancing immune response against tumor cells
  • Promotes durable antitumor activity by preventing immune evasion
• Administration:
  • Intravenous infusion, typically every 3 weeks
  • Dose adjustments may be required based on toxicity or immune-related adverse events
• Common Side Effects:
  • Fatigue, rash, diarrhea, musculoskeletal pain
  • Immune-related adverse events (e.g., pneumonitis, colitis, hepatitis, endocrinopathies) require prompt recognition and management
• Clinical Impact:
  • Demonstrated significant survival benefit in advanced CSCC
  • Cost-effective compared to historical standard therapies

Synonyms

Libtayo

Links